| Literature DB >> 33664238 |
Yuesheng Lv1, Wenjing Zhang1, Jinyao Zhao1, Bing Sun2, Yangfan Qi1, Haoyu Ji1, Chaoqun Chen1, Jinrui Zhang1, Junxiu Sheng3, Taishu Wang1, Daniel Dominguez4, Han Liu1, Quentin Liu1, Songshu Meng1, Xiaoling Li5, Yang Wang6.
Abstract
Alternative splicing is a critical process to generate protein diversity. However, whether and how alternative splicing regulates autophagy remains largely elusive. Here we systematically identify the splicing factor SRSF1 as an autophagy suppressor. Specifically, SRSF1 inhibits autophagosome formation by reducing the accumulation of LC3-II and numbers of autophagosomes in different cell lines. Mechanistically, SRSF1 promotes the splicing of the long isoform of Bcl-x that interacts with Beclin1, thereby dissociating the Beclin1-PIK3C3 complex. In addition, SRSF1 also directly interacts with PIK3C3 to disrupt the interaction between Beclin1 and PIK3C3. Consequently, the decrease of SRSF1 stabilizes the Beclin1 and PIK3C3 complex and activates autophagy. Interestingly, SRSF1 can be degraded by starvation- and oxidative stresses-induced autophagy through interacting with LC3-II, whereas reduced SRSF1 further promotes autophagy. This positive feedback is critical to inhibiting Gefitinib-resistant cancer cell progression both in vitro and in vivo. Consistently, the expression level of SRSF1 is inversely correlated to LC3 level in clinical cancer samples. Our study not only provides mechanistic insights of alternative splicing in autophagy regulation but also discovers a new regulatory role of SRSF1 in tumorigenesis, thereby offering a novel avenue for potential cancer therapeutics.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33664238 PMCID: PMC7933324 DOI: 10.1038/s41392-021-00495-6
Source DB: PubMed Journal: Signal Transduct Target Ther ISSN: 2059-3635